Why Pfizer ' s stumble in the obesity market is a boon for Eli Lilly

has suffered another setback in its efforts to develop a weight-loss pill — and that's good news for Club holding Eli Lilly (LLY) as it looks to maintain an edge in the fast-growing obesity-treatment market. Pfizer said Friday it will discontinue its twice-daily weight-loss pill, danuglipron,…#club #elililly #lly #pfizer #jimcramer #sp500 #ytd #danish #novonordisk #nvo
Source: Reuters: Health - Category: Consumer Health News Source Type: news